CBS-006 - Associations between serum tocilizumab level, interleukin-6, and endogenous markers of CYP3A activity in patients with rheumatoid arthritis

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: CBS-006
• By: MOCHIZUKI, Takashi (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Japan)
• Co-author(s): Takashi Mochizuki (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu city, Shizuoka, Japan)
  Kaito Shibata (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu city, Shizuoka, Japan / Department of Pharmacy, Shinshu University Hospital, Matsumoto city, Nagano, Japan)
  Takafumi Naito (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu city, Shizuoka, Japan / Department of Pharmacy, Shinshu University Hospital, Matsumoto city, Nagano, Japan)
  Kumiko Shimoyama (Division of Immunology and Rheumatology, Department of Internal Medicine Ⅲ, Hamamatsu University School of Medicine, Hamamatsu city, Shizuoka, Japan)
  Noriyoshi Ogawa (Division of Immunology and Rheumatology, Department of Internal Medicine Ⅲ, Hamamatsu University School of Medicine, Hamamatsu city, Shizuoka, Japan)
  Junichi Kawakami (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu city, Shizuoka, Japan)
  
• Abstract:

  Introduction
  Tocilizumab, an anti-interleukin-6 (IL-6) receptor monoclonal antibody, is widely used for the treatment of rheumatoid arthritis (RA). Pharmacokinetic drug interactions between biologics and low molecular-weight drugs have been reported in clinical settings. Tocilizumab may alter the activity of cytochrome P450 (CYP) 3A by modulating..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login